;PMID: 11717184
;source_file_974.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..166] = [t:49..166]
;2)section:[e:170..217] = [t:170..217]
;3)section:[e:221..337] = [t:221..337]
;4)sentence:[e:341..620] = [t:341..620]
;5)sentence:[e:621..800] = [t:621..800]
;6)sentence:[e:801..936] = [t:801..936]
;7)sentence:[e:937..1064] = [t:937..1064]
;8)sentence:[e:1065..1230] = [t:1065..1230]
;9)sentence:[e:1231..1380] = [t:1231..1380]
;10)sentence:[e:1381..1430] = [t:1381..1430]
;11)sentence:[e:1431..1670] = [t:1431..1670]
;12)sentence:[e:1672..1868] = [t:1672..1868]
;13)sentence:[e:1869..2132] = [t:1869..2132]
;14)section:[e:2136..2181] = [t:2136..2181]

;section 0 Span:0..43
;Drug Metab Dispos. 2001 Dec;29(12):1644-51.
(SEC
  (FRAG (NNP:[0..4] Drug) (NNP:[5..10] Metab) (NNP:[11..17] Dispos)
        (.:[17..18] .) (CD:[19..23] 2001) (CC:[24..31] Dec;29-LRB-)
        (CD:[31..33] 12) (-RRB-:[33..34] -RRB-) (CD:[34..39] :1644)
        (::[39..40] -) (CD:[40..42] 51) (.:[42..43] .)))

;sentence 1 Span:49..166
;Multisite kinetic models for CYP3A4: simultaneous activation and inhibition
;of  diazepam and testosterone metabolism.
;[78..84]:cyp450:"CYP3A4"
;[129..137]:substance:"diazepam"
;[142..154]:substance:"testosterone"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[49..58] Multisite) (JJ:[59..66] kinetic) (NNS:[67..73] models))
      (PP (IN:[74..77] for)
        (NP (NN:[78..84] CYP3A4))))
    (::[84..85] :)
    (NP
      (NP (JJ:[86..98] simultaneous) (NN:[99..109] activation)
          (CC:[110..113] and) (NN:[114..124] inhibition))
      (PP (IN:[125..127] of)
        (NP
          (NP (NN:[129..137] diazepam)
            (NML-1 (-NONE-:[137..137] *P*)))
          (CC:[138..141] and)
          (NP (NN:[142..154] testosterone)
            (NML-1 (NN:[155..165] metabolism))))))
    (.:[165..166] .)))

;section 2 Span:170..217
;Kenworthy KE, Clarke SE, Andrews J, Houston JB.
(SEC
  (FRAG (NNP:[170..179] Kenworthy) (NNP:[180..182] KE) (,:[182..183] ,)
        (NNP:[184..190] Clarke) (NNP:[191..193] SE) (,:[193..194] ,)
        (NNP:[195..202] Andrews) (NNP:[203..205] J,) (NNP:[206..213] Houston)
        (NNP:[214..217] JB.)))

;section 3 Span:221..337
;Department of Mechanism and Extrapolation Technologies, GlaxoSmithKline, The 
;Frythe, Welwyn, Herts, United Kingdom.
(SEC
  (FRAG (NNP:[221..231] Department) (IN:[232..234] of)
        (NNP:[235..244] Mechanism) (CC:[245..248] and)
        (NNP:[249..262] Extrapolation) (NNPS:[263..275] Technologies)
        (,:[275..276] ,) (NNP:[277..292] GlaxoSmithKline) (,:[292..293] ,)
        (DT:[294..297] The) (NNP:[299..305] Frythe) (,:[305..306] ,)
        (NNP:[307..313] Welwyn) (,:[313..314] ,) (NNP:[315..320] Herts)
        (,:[320..321] ,) (NNP:[322..328] United) (NNP:[329..336] Kingdom)
        (.:[336..337] .)))

;sentence 4 Span:341..620
;Some substrates of cytochrome P450 (CYP) 3A4, the most abundant CYP in the
;human  liver responsible for the metabolism of many structurally diverse
;therapeutic  agents, do not obey classical Michaelis-Menten kinetics and
;demonstrate  homotropic and/or heterotropic cooperativity.
;[346..356]:substance:"substrates"
;[360..385]:cyp450:"cytochrome P450 (CYP) 3A4"
;[405..408]:cyp450:"CYP"
;[502..508]:substance:"agents"
;[532..557]:quantitative-name:"Michaelis-Menten kinetics"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[341..345] Some) (NNS:[346..356] substrates))
        (PP (IN:[357..359] of)
          (NP
            (NML
              (NML (NN:[360..370] cytochrome) (NN:[371..375] P450))
              (NML (-LRB-:[376..377] -LRB-) (NN:[377..380] CYP)
                   (-RRB-:[380..381] -RRB-)))
            (NN:[382..385] 3A4))))
      (,:[385..386] ,)
      (NP
        (NP
          (NP (DT:[387..390] the)
            (ADJP (RBS:[391..395] most) (JJ:[396..404] abundant))
            (NN:[405..408] CYP))
          (PP (IN:[409..411] in)
            (NP (DT:[412..415] the) (JJ:[416..421] human) (NN:[423..428] liver))))
        (ADJP (JJ:[429..440] responsible)
          (PP (IN:[441..444] for)
            (NP
              (NP (DT:[445..448] the) (NN:[449..459] metabolism))
              (PP (IN:[460..462] of)
                (NP (JJ:[463..467] many)
                  (ADJP (RB:[468..480] structurally) (JJ:[481..488] diverse))
                  (JJ:[489..500] therapeutic) (NNS:[502..508] agents))))))))
    (,:[508..509] ,)
    (VP (VBP:[510..512] do) (RB:[513..516] not)
      (VP
        (VP (VB:[517..521] obey)
          (NP (JJ:[522..531] classical)
            
            (NML (NNP:[532..541] Michaelis) (HYPH:[541..542] -)
                 (NNP:[542..548] Menten))
            (NNS:[549..557] kinetics)))
        (CC:[558..561] and)
        (VP (VBP:[562..573] demonstrate)
          (NP
            (NP (JJ:[575..585] homotropic)
              (NML-1 (-NONE-:[585..585] *P*)))
            (CC:[586..592] and/or)
            (NP (JJ:[593..605] heterotropic)
              (NML-1 (NN:[606..619] cooperativity)))))))
    (.:[619..620] .)))

;sentence 5 Span:621..800
;The unusual kinetics and  differential effects observed between substrates of
;this enzyme confound the  prediction of drug clearance and drug-drug
;interactions from in vitro data.
;[685..695]:substance:"substrates"
;[704..710]:substance:"enzyme"
;[739..743]:substance:"drug"
;[758..762]:substance:"drug"
;[763..767]:substance:"drug"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[621..624] The)
        (NML
          (NML (JJ:[625..632] unusual) (NNS:[633..641] kinetics))
          (CC:[642..645] and)
          (NML (JJ:[647..659] differential) (NNS:[660..667] effects))))
      (VP (VBN:[668..676] observed)
        (NP (-NONE-:[676..676] *))
        (PP (IN:[677..684] between)
          (NP
            (NP (NNS:[685..695] substrates))
            (PP (IN:[696..698] of)
              (NP (DT:[699..703] this) (NN:[704..710] enzyme)))))))
    (VP (VBP:[711..719] confound)
      (NP
        (NP (DT:[720..723] the) (NN:[725..735] prediction))
        (PP (IN:[736..738] of)
          (NP
            (NP (NN:[739..743] drug) (NN:[744..753] clearance))
            (CC:[754..757] and)
            (NP
              (NML
                (NML (NN:[758..762] drug))
                (PP (HYPH:[762..763] -)
                  (NP (NN:[763..767] drug))))
              (NNS:[768..780] interactions))))
        (PP (IN:[781..785] from)
          (NP
            (ADJP (FW:[786..788] in) (FW:[789..794] vitro))
            (NN:[795..799] data)))))
    (.:[799..800] .)))

;sentence 6 Span:801..936
;We  have investigated the hypothesis that CYP3A4 may bind multiple molecules 
;simultaneously using diazepam (DZ) and testosterone (TS).
;[843..849]:cyp450:"CYP3A4"
;[900..908]:substance:"diazepam"
;[910..912]:substance:"DZ"
;[918..930]:substance:"testosterone"
;[932..934]:substance:"TS"
(SENT
  (S
    (NP-SBJ (PRP:[801..803] We))
    (VP (VBP:[805..809] have)
      (VP (VBN:[810..822] investigated)
        (NP (DT:[823..826] the) (NN:[827..837] hypothesis)
          (SBAR (IN:[838..842] that)
            (S
              (NP-SBJ (NN:[843..849] CYP3A4))
              (VP (MD:[850..853] may)
                (VP (VB:[854..858] bind)
                  (NP (JJ:[859..867] multiple) (NNS:[868..877] molecules))
                  (ADVP (RB:[879..893] simultaneously))
                  (S-MNR
                    (NP-SBJ (-NONE-:[893..893] *))
                    (VP (VBG:[894..899] using)
                      (NP
                        (NP
                          (NP (NN:[900..908] diazepam))
                          (NP (-LRB-:[909..910] -LRB-) (NN:[910..912] DZ)
                              (-RRB-:[912..913] -RRB-)))
                        (CC:[914..917] and)
                        (NP
                          (NP (NN:[918..930] testosterone))
                          (NP (-LRB-:[931..932] -LRB-) (NN:[932..934] TS)
                              (-RRB-:[934..935] -RRB-)))))))))))))
    (.:[935..936] .)))

;sentence 7 Span:937..1064
;Both substrates showed  sigmoidal kinetics in B-lymphoblastoid microsomes
;containing a recombinant human  CYP3A4 and reductase.
;[942..952]:substance:"substrates"
;[1043..1049]:cyp450:"CYP3A4"
;[1054..1063]:substance:"reductase"
(SENT
  (S
    (NP-SBJ (DT:[937..941] Both) (NNS:[942..952] substrates))
    (VP (VBD:[953..959] showed)
      (NP (JJ:[961..970] sigmoidal) (NNS:[971..979] kinetics))
      (PP-LOC (IN:[980..982] in)
        (NP
          (NP (JJ:[983..999] B-lymphoblastoid) (NNS:[1000..1010] microsomes))
          (VP (VBG:[1011..1021] containing)
            (NP
              (NP (DT:[1022..1023] a) (JJ:[1024..1035] recombinant)
                  (JJ:[1036..1041] human) (NN:[1043..1049] CYP3A4))
              (CC:[1050..1053] and)
              (NP (NN:[1054..1063] reductase)))))))
    (.:[1063..1064] .)))

;sentence 8 Span:1065..1230
;When analyzed in combination, TS activated the formation  of
;3-hydroxydiazepam (3HDZ) and N-desmethyldiazepam (NDZ) (maximal activation 
;374 and 205%, respectively).
;[1095..1097]:substance:"TS"
;[1126..1143]:substance:"3-hydroxydiazepam"
;[1145..1149]:substance:"3HDZ"
;[1155..1174]:substance:"N-desmethyldiazepam"
;[1176..1179]:substance:"NDZ"
;[1182..1200]:quantitative-name:"maximal activation"
;[1202..1205]...[1213..1214]:quantitative-value:"374"..."%"
;[1210..1214]:quantitative-value:"205%"
(SENT
  (S
    (SBAR-ADV
      (WHADVP-1 (WRB:[1065..1069] When))
      (S
        (NP-SBJ-2 (-NONE-:[1069..1069] *))
        (VP (VBN:[1070..1078] analyzed)
          (NP-2 (-NONE-:[1078..1078] *))
          (PP (IN:[1079..1081] in)
            (NP (NN:[1082..1093] combination)))
          (ADVP-TMP-1 (-NONE-:[1093..1093] *T*)))))
    (,:[1093..1094] ,)
    (NP-SBJ (NN:[1095..1097] TS))
    (VP (VBD:[1098..1107] activated)
      (NP
        (NP (DT:[1108..1111] the) (NN:[1112..1121] formation))
        (PP (IN:[1123..1125] of)
          (NP
            (NP
              (NP (NN:[1126..1143] 3-hydroxydiazepam))
              (NP (-LRB-:[1144..1145] -LRB-) (NN:[1145..1149] 3HDZ)
                  (-RRB-:[1149..1150] -RRB-)))
            (CC:[1151..1154] and)
            (NP
              (NP (NN:[1155..1174] N-desmethyldiazepam))
              (NP (-LRB-:[1175..1176] -LRB-) (NN:[1176..1179] NDZ)
                  (-RRB-:[1179..1180] -RRB-))))))
      (PRN (-LRB-:[1181..1182] -LRB-)
        (S
          (NP-SBJ (JJ:[1182..1189] maximal) (NN:[1190..1200] activation))
          (NP-PRD
            (NP (CD:[1202..1205] 374)
              (NML-3 (-NONE-:[1205..1205] *P*)))
            (CC:[1206..1209] and)
            (NP (CD:[1210..1213] 205)
              (NML-3 (NN:[1213..1214] %))))
          (,:[1214..1215] ,)
          (ADVP (RB:[1216..1228] respectively)))
        (-RRB-:[1228..1229] -RRB-)))
    (.:[1229..1230] .)))

;sentence 9 Span:1231..1380
;For 3HDZ, V(max) values remained constant with  increasing TS, whereas the
;S(50) and Hill values decreased, tending to make the  data less sigmoidal.
;[1235..1239]:substance:"3HDZ"
;[1241..1247]:quantitative-name:"V(max)"
;[1290..1292]:substance:"TS"
;[1306..1311]:quantitative-name:"S(50)"
(SENT
  (S
    (PP (IN:[1231..1234] For)
      (NP (NN:[1235..1239] 3HDZ)))
    (,:[1239..1240] ,)
    (NP-SBJ (NN:[1241..1247] V-LRB-max-RRB-) (NNS:[1248..1254] values))
    (VP (VBD:[1255..1263] remained)
      (ADJP-PRD (JJ:[1264..1272] constant))
      (PP (IN:[1273..1277] with)
        (NP (VBG:[1279..1289] increasing) (NN:[1290..1292] TS)))
      (,:[1292..1293] ,)
      (SBAR-ADV (IN:[1294..1301] whereas)
        (S
          (NP-SBJ (DT:[1302..1305] the)
            (NML
              (NML (NN:[1306..1311] S-LRB-50-RRB-)
                (NML-1 (-NONE-:[1311..1311] *P*)))
              (CC:[1312..1315] and)
              (NML (NNP:[1316..1320] Hill)
                (NML-1 (NNS:[1321..1327] values)))))
          (VP (VBD:[1328..1337] decreased) (,:[1337..1338] ,)
            (S-ADV
              (NP-SBJ (-NONE-:[1338..1338] *))
              (VP (VBG:[1339..1346] tending)
                (S
                  (NP-SBJ (-NONE-:[1346..1346] *))
                  (VP (TO:[1347..1349] to)
                    (VP (VB:[1350..1354] make)
                      (S
                        (NP-SBJ (DT:[1355..1358] the) (NN:[1360..1364] data))
                        (ADJP-PRD (RBR:[1365..1369] less)
                                  (JJ:[1370..1379] sigmoidal))))))))))))
    (.:[1379..1380] .)))

;sentence 10 Span:1381..1430
;Similar trends were observed for the NDZ pathway.
;[1418..1421]:substance:"NDZ"
(SENT
  (S
    (NP-SBJ-1 (JJ:[1381..1388] Similar) (NNS:[1389..1395] trends))
    (VP (VBD:[1396..1400] were)
      (VP (VBN:[1401..1409] observed)
        (NP-1 (-NONE-:[1409..1409] *))
        (PP (IN:[1410..1413] for)
          (NP (DT:[1414..1417] the) (NN:[1418..1421] NDZ)
              (NN:[1422..1429] pathway)))))
    (.:[1429..1430] .)))

;sentence 11 Span:1431..1670
;DZ  inhibited the formation 6beta-hydroxytestosterone (maximal inhibition,
;45% of  control), causing a decrease in V(max) but no significant change to
;the S(50)  and Hill values, suggesting that DZ may inhibit via a separate
;effector site.
;[1431..1433]:substance:"DZ"
;[1459..1484]:substance:"6beta-hydroxytestosterone"
;[1486..1504]:quantitative-name:"maximal inhibition"
;[1506..1509]:quantitative-value:"45%"
;[1546..1552]:quantitative-name:"V(max)"
;[1586..1591]:quantitative-name:"S(50)"
;[1626..1628]:substance:"DZ"
(SENT
  (S
    (NP-SBJ (NN:[1431..1433] DZ))
    (VP (VBD:[1435..1444] inhibited)
      (NP (DT:[1445..1448] the) (NN:[1449..1458] formation)
          (NN:[1459..1484] 6beta-hydroxytestosterone)
        (PRN (-LRB-:[1485..1486] -LRB-)
          (S
            (NP-SBJ (JJ:[1486..1493] maximal) (NN:[1494..1504] inhibition))
            (,:[1504..1505] ,)
            (NP-PRD
              (NP (CD:[1506..1508] 45) (NN:[1508..1509] %))
              (PP (IN:[1510..1512] of)
                (NP (NN:[1514..1521] control)))))
          (-RRB-:[1521..1522] -RRB-)))
      (,:[1522..1523] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1523..1523] *))
        (VP (VBG:[1524..1531] causing)
          (NP
            (NP
              (NP (DT:[1532..1533] a) (NN:[1534..1542] decrease))
              (PP (IN:[1543..1545] in)
                (NP (NN:[1546..1552] V-LRB-max-RRB-))))
            (CC:[1553..1556] but)
            (NP
              (NP (DT:[1557..1559] no) (JJ:[1560..1571] significant)
                  (NN:[1572..1578] change))
              (PP (TO:[1579..1581] to)
                (NP (DT:[1582..1585] the)
                  (NML
                    (NML (NN:[1586..1591] S-LRB-50-RRB-)
                      (NML-1 (-NONE-:[1591..1591] *P*)))
                    (CC:[1593..1596] and)
                    (NML (NNP:[1597..1601] Hill)
                      (NML-1 (NNS:[1602..1608] values))))))))
          (,:[1608..1609] ,)
          (S-ADV
            (NP-SBJ (-NONE-:[1609..1609] *))
            (VP (VBG:[1610..1620] suggesting)
              (SBAR (IN:[1621..1625] that)
                (S
                  (NP-SBJ (NN:[1626..1628] DZ))
                  (VP (MD:[1629..1632] may)
                    (VP (VB:[1633..1640] inhibit)
                      (PP (IN:[1641..1644] via)
                        (NP (DT:[1645..1646] a) (JJ:[1647..1655] separate)
                            (NN:[1656..1664] effector) (NN:[1665..1669] site))))))))))))
    (.:[1669..1670] .)))

;sentence 12 Span:1672..1868
;Multisite rate equation models have been derived to explore the analysis of
;such  complex kinetic data and to allow accurate determination of the kinetic
; parameters for activation and inhibition.
(SENT
  (S
    (NP-SBJ-1 (JJ:[1672..1681] Multisite) (NN:[1682..1686] rate)
              (NN:[1687..1695] equation) (NNS:[1696..1702] models))
    (VP (VBP:[1703..1707] have)
      (VP (VBN:[1708..1712] been)
        (VP (VBN:[1713..1720] derived)
          (NP-1 (-NONE-:[1720..1720] *))
          (S-PRP
            (NP-SBJ (-NONE-:[1720..1720] *))
            (VP
              (VP (TO:[1721..1723] to)
                (VP (VB:[1724..1731] explore)
                  (NP
                    (NP (DT:[1732..1735] the) (NN:[1736..1744] analysis))
                    (PP (IN:[1745..1747] of)
                      (NP (JJ:[1748..1752] such) (JJ:[1754..1761] complex)
                          (JJ:[1762..1769] kinetic) (NN:[1770..1774] data))))))
              (CC:[1775..1778] and)
              (VP (TO:[1779..1781] to)
                (VP (VB:[1782..1787] allow)
                  (NP
                    (NP (JJ:[1788..1796] accurate)
                        (NN:[1797..1810] determination))
                    (PP (IN:[1811..1813] of)
                      (NP
                        (NP (DT:[1814..1817] the) (JJ:[1818..1825] kinetic)
                            (NNS:[1827..1837] parameters))
                        (PP (IN:[1838..1841] for)
                          (NP (NN:[1842..1852] activation) (CC:[1853..1856] and)
                              (NN:[1857..1867] inhibition)))))))))))))
    (.:[1867..1868] .)))

;sentence 13 Span:1869..2132
;The data and models presented are  consistent with proposals that CYP3A4 can
;bind and metabolize multiple substrate  molecules simultaneously; they also
;provide a generic solution for the  interpretation of the complex kinetic
;data derived from CYP3A4 substrates.
;[1935..1941]:cyp450:"CYP3A4"
;[1975..1984]:substance:"substrate"
;[2114..2120]:cyp450:"CYP3A4"
;[2121..2131]:substance:"substrates"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[1869..1872] The) (NN:[1873..1877] data) (CC:[1878..1881] and)
            (NNS:[1882..1888] models))
        (VP (VBN:[1889..1898] presented)
          (NP (-NONE-:[1898..1898] *))))
      (VP (VBP:[1899..1902] are)
        (ADJP-PRD (JJ:[1904..1914] consistent)
          (PP (IN:[1915..1919] with)
            (NP
              (NP (NNS:[1920..1929] proposals))
              (SBAR (IN:[1930..1934] that)
                (S
                  (NP-SBJ (NN:[1935..1941] CYP3A4))
                  (VP (MD:[1942..1945] can)
                    (VP (VB:[1946..1950] bind) (CC:[1951..1954] and)
                        (VB:[1955..1965] metabolize)
                      (NP (JJ:[1966..1974] multiple) (NN:[1975..1984] substrate)
                          (NNS:[1986..1995] molecules))
                      (ADVP (RB:[1996..2010] simultaneously)))))))))))
    (::[2010..2011] ;)
    (S
      (NP-SBJ (PRP:[2012..2016] they))
      (ADVP (RB:[2017..2021] also))
      (VP (VBP:[2022..2029] provide)
        (NP
          (NP (DT:[2030..2031] a) (JJ:[2032..2039] generic)
              (NN:[2040..2048] solution))
          (PP (IN:[2049..2052] for)
            (NP
              (NP (DT:[2053..2056] the) (NN:[2058..2072] interpretation))
              (PP (IN:[2073..2075] of)
                (NP
                  (NP (DT:[2076..2079] the) (JJ:[2080..2087] complex)
                      (JJ:[2088..2095] kinetic) (NN:[2096..2100] data))
                  (VP (VBN:[2101..2108] derived)
                    (NP (-NONE-:[2108..2108] *))
                    (PP (IN:[2109..2113] from)
                      (NP (NN:[2114..2120] CYP3A4) (NNS:[2121..2131] substrates)))))))))))
    (.:[2131..2132] .)))

;section 14 Span:2136..2181
;PMID: 11717184 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2136..2140] PMID) (::[2140..2141] :) (CD:[2142..2150] 11717184)
        (IN:[2151..2152] -LSB-) (NNP:[2152..2158] PubMed) (HYPH:[2159..2160] -)
        (JJ:[2161..2168] indexed) (IN:[2169..2172] for)
        (NNP:[2173..2181] MEDLINE-RSB-)))
